15 October 2015 - Nivolumab (Opdivo) has been approved since June 2015 for use by adults with advanced melanoma. The Institute for Quality and Efficiency in Health Care (IQWiG) has sought to determine whether it offers an additional clinical benefit.

There is a survival benefit in treatment-naïve patients whose tumour is BRAF-V600 mutation negative. However, this varies with gender. In the overall picture, IQWiG has found there is an indication of a considerable added clinical benefit in women and a clue (hint) of a low additional clinical benefit in men.

For other patient populations, the dossier did not contain any usable data.

For more details, go to: https://www.iqwig.de/de/presse/pressemitteilungen/pressemitteilungen/nivolumab-bei-schwarzem-hautkrebs-zusatznutzen-bei-bestimmten-patienten.6926.html?&et_cid=4&et_lid=%25208